ACADIA Pharmaceuticals Inc. Common Stock (ACAD)

FairStock Score: 77/100 — HIGH CONVICTION

Key Financials

Strengths

• High return on equity of 39.9% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.04, providing financial flexibility
• Altman Z-Score of 5.9 confirms minimal bankruptcy risk and strong solvency
• Superior net profit margin of 25.5% indicating pricing power and operational efficiency
• FairStock composite score of 77/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

ACADIA Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $3.8 billion. The business generates $1.1 billion in annual revenue with a 25.5% net margin. From a quality standpoint, ACADIA shows Altman Z-Score of 5.9 confirms fortress-level solvency and strong 40% ROE. On valuation, the stock is deeply undervalued on a P/E basis at 9.6x, with trades above its Graham Number with a negative 15% margin. Growth dynamics show revenue growing at 9.4% and profit growth of 90.3%. Our composite FairStock Score of 77/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates ACADIA's consistent 40% ROE at just 10x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer